Many antibiotics identified in the past were not further studied and developed for therapeutic use. Reasons include the under-appreciation of the challenge of antimicrobial resistance for human therapy some decades ago as well as a lack of economic feasibility of access to natural product scaffolds often exhibiting challenging chemical structures. In addition, our understanding of the global importance of bacterial pathogens has shifted over time and led to the announcement of the WHO priority list of most important species.